NEW YORK, May 20, 2026, 16:04 EDT
Revelation Biosciences shares were quoted at $1.09 after the U.S. market close on Wednesday, up $0.06, or 5.82%, giving the clinical-stage biotech a market value of about $4.1 million. The move beat a firmer Nasdaq session, with the broader index up about 1.55% late in the day.
The gain was not a catch-up trade after a holiday. Nasdaq’s 2026 calendar lists Memorial Day on May 25 as the next U.S. market closure, leaving Wednesday as a regular trading session for REVB.
That matters because there was no same-day corporate headline to explain the move. Revelation’s own news page showed its latest company press release was a May 11 corporate update letter, following May 7 first-quarter results, so the stock appeared to be trading on positioning around recent disclosures rather than a fresh data release.
The investor question is now narrow: can Revelation get Gemini, its lead immune-modulation drug candidate, into the next study before the balance sheet becomes the story again. Chief Executive James Rolke told stockholders the company was working to begin an adaptive-design clinical study in acute kidney injury, or AKI, in the fourth quarter; an adaptive design is a trial format that can shift parts of the study, such as dose selection, under pre-set rules.
A filing also showed investors will vote June 24 on whether to let the board carry out one or more reverse stock splits, ranging from 1-for-2 to as much as 1-for-250. A reverse split reduces the number of shares outstanding while raising the per-share price, often used by small Nasdaq companies trying to preserve listing flexibility.
Revelation reported $14.1 million in cash and cash equivalents at March 31, up from $10.7 million at year-end, helped by $6.7 million from a January warrant inducement. The company posted a first-quarter net loss of $3.0 million, or $2.71 per share, and Rolke said, “Our focus remains on getting our pivotal clinical study” of Gemini in AKI patients underway. Revelation BioSciences
The trial path is the main reason the stock still gets attention despite its size. Revelation said in January it had reached agreement with the FDA on a single adaptive Phase 2/3 study, with a main endpoint built around death and/or need for dialysis; dialysis is a treatment that filters blood when kidneys can no longer do the job well enough.
The company has also put outside clinical names around the program. Laurence Busse, M.D., a principal investigator and Emory physician, said in April that AKI has a “clear necessity for novel therapeutic approaches that move beyond supportive care alone,” when Revelation announced an AKI advisory board. Revelation BioSciences
Brad Sorensen at Zacks Small-Cap Research wrote in a May 8 sponsored report that the first-quarter update showed “good cash and a solid balance sheet,” while rating the stock’s risk level as high and keeping a $22.50 valuation. The same report disclosed Zacks SCR had received compensation from the issuer or related parties for non-investment-banking services.
But the downside case is blunt. Revelation’s 10-Q said its cash would not be enough to sustain operations for one year after the March 31 financial statements were issued, “which raises substantial doubt” about its ability to continue as a going concern — accounting language for whether a company can keep operating without more funding. The filing said Revelation would need to raise capital and could be forced to delay, reduce or eliminate research and development programs if it cannot obtain financing. SEC
Competition for investor money in kidney-drug stocks is also tougher than REVB’s market value suggests. Travere Therapeutics won an FDA expansion last month for Filspari in focal segmental glomerulosclerosis, another serious kidney disease, while ProKidney says it is running a Phase 3 study in advanced chronic kidney disease; neither is a one-for-one AKI rival, but both show how crowded and milestone-driven the kidney field has become.
For now, REVB is trading less like a revenue story and more like a calendar stock. The next proof points are funding, the June vote and evidence that the Gemini trial really starts on the timetable management has laid out.
